Jinyu Bio-Technology Co., Ltd. Class A

Jinyu Bio-Technology Co., Ltd. Class A

SSSE:600201
11.90
CNY
-0.10
(-0.83%)
0.16EPS
78.27P/E
12.77BMarket Cap
Apr 16Next Earn

Total Valuation

CNY

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A carries a market capitalization of 12.77B, placing it among publicly traded companies globally. Its enterprise value stands at 11.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.77B
Enterprise Value11.46B

Important Dates

Jinyu Bio-Technology Co., Ltd. Class A's next confirmed earnings release is scheduled for April 16, 2027.

Earnings Date4/16/2027

Share Statistics

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A has 1.10B shares outstanding.

Shares Outstanding1.10B

Valuation Ratios

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 78.27. The price-to-sales ratio is 8.04, and the price-to-book ratio stands at 2.42.

PE Ratio78.27
PS Ratio8.04
PB Ratio2.42
P/TBV Ratio2.85

Enterprise Valuation

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A trades at an EV/EBITDA multiple of 54.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 54.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.46B versus a market cap of 12.77B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.15
EV / EBITDA54.60
EV / EBIT54.60

Financial Position

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.02, indicating elevated leverage, while an interest coverage ratio of 182.20 demonstrates strong ability to service its debt obligations.

Current Ratio4.44
Quick Ratio2.64
Debt / Equity5.02
Debt / EBITDA1.29
Interest Coverage182.20

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A posted a return on equity (ROE) of 3.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.16 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.77, useful for judging operating efficiency across full business cycles. The company generates approximately 852,620.11 in revenue per employee across its workforce of 1,881.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.73 indicates how many times Jinyu Bio-Technology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.10
Return on Assets (ROA)2.50
Return on Invested Capital (ROIC)3.16
Return on Capital Employed (ROCE)2.77
Revenue Per Employee852,620.11
Employee Count1,881.00
Inventory Turnover2.73

Taxes

CNY

Over the twelve months ended September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A recorded 32.66M in income tax expense. That works out to an effective tax rate of 15.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 208.76M, leaving 164.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax32.66M
Effective Tax Rate15.64

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jinyu Bio-Technology Co., Ltd. Class A's stock has declined approximately 1.08% over the past 52 weeks. The 50-day moving average sits at 12.11, while the 200-day moving average is 13.42.

52-Week Price Change-1.08%
50-Day Moving Average12.11
200-Day Moving Average13.42

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A generated 1.60B in revenue and converted that into 164.72M in net income, yielding earnings per share of 0.16. EBITDA reached 209.88M, while operating income came in at 322.67M.

Revenue1.60B
Gross Profit881.59M
Operating Income322.67M
Pretax Income208.76M
Net Income164.72M
EBITDA209.88M
EBIT209.88M
Earnings Per Share (EPS)0.16

Balance Sheet

CNY

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A holds 1.70B in cash and equivalents against 270.70M in total debt, resulting in a net debt position of -1.20B. Total book value stands at 5.27B, with working capital of 2.22B providing operational flexibility.

Cash & Cash Equivalents1.70B
Total Debt270.70M
Net Debt-1.20B
Equity (Book Value)5.27B
Book Value Per Share4.79
Working Capital2.22B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-123.46M

Margins

Over the twelve months ended September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A posted a gross margin of 54.97, reflecting its pricing power and cost economics. The operating margin of 20.12 and net profit margin of 10.27 provide insight into operational efficiency.

Gross Margin54.97
Operating Margin20.12
Pretax Margin13.02
Profit Margin10.27
EBITDA Margin13.09

Dividends & Yields

Over the twelve months ended September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.72 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jinyu Bio-Technology Co., Ltd. Class A shareholders.

Payout Ratio-0.72
Shareholder Yield2.05

Stock Splits

Jinyu Bio-Technology Co., Ltd. Class A's most recent stock split took place on June 25, 2018 with a 10:13 split ratio.

Last Split Date6/25/2018
Split Ratio10:13

Scores

As of September 30, 2026, Jinyu Bio-Technology Co., Ltd. Class A has an Altman Z-Score of 7.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.97